187 related articles for article (PubMed ID: 26296913)
1. Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines.
Totaro KA; Barthelme D; Simpson PT; Sauer RT; Sello JK
Bioorg Med Chem; 2015 Sep; 23(18):6218-22. PubMed ID: 26296913
[TBL] [Abstract][Full Text] [Related]
2. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells.
Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS
Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Activity of Isosyringolin A.
Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
[TBL] [Abstract][Full Text] [Related]
4. Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.
Totaro KA; Barthelme D; Simpson PT; Jiang X; Lin G; Nathan CF; Sauer RT; Sello JK
ACS Infect Dis; 2017 Feb; 3(2):176-181. PubMed ID: 28183185
[TBL] [Abstract][Full Text] [Related]
5. Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
Opoku-Ansah J; Ibarra-Rivera TR; Pirrung MC; Bachmann AS
Pharm Biol; 2012 Jan; 50(1):25-9. PubMed ID: 22196580
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship study of syringolin A as a potential anticancer agent.
Chiba T; Matsuda A; Ichikawa S
Bioorg Med Chem Lett; 2015 Nov; 25(21):4872-4877. PubMed ID: 26231162
[TBL] [Abstract][Full Text] [Related]
7. Modulation of proteasome subunit selectivity of syringolins.
Tatsumi K; Kitahata S; Komatani Y; Katsuyama A; Yakushiji F; Ichikawa S
Bioorg Med Chem; 2024 May; 106():117733. PubMed ID: 38704960
[TBL] [Abstract][Full Text] [Related]
8. The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity.
Clerc J; Li N; Krahn D; Groll M; Bachmann AS; Florea BI; Overkleeft HS; Kaiser M
Chem Commun (Camb); 2011 Jan; 47(1):385-7. PubMed ID: 20830349
[TBL] [Abstract][Full Text] [Related]
9. Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor.
Trivella DB; Pereira AR; Stein ML; Kasai Y; Byrum T; Valeriote FA; Tantillo DJ; Groll M; Gerwick WH; Moore BS
Chem Biol; 2014 Jun; 21(6):782-91. PubMed ID: 24930969
[TBL] [Abstract][Full Text] [Related]
10. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
[TBL] [Abstract][Full Text] [Related]
11. Novel proteasome-inhibitory syrbactin analogs inducing endoplasmic reticulum stress and apoptosis in hematological tumor cell lines.
Anshu A; Thomas S; Agarwal P; Ibarra-Rivera TR; Pirrung MC; Schönthal AH
Biochem Pharmacol; 2011 Sep; 82(6):600-9. PubMed ID: 21736873
[TBL] [Abstract][Full Text] [Related]
12. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
Qin JM; Huang RZ; Yao GY; Liao ZX; Pan YM; Wang HS
Eur J Med Chem; 2017 Jan; 126():259-269. PubMed ID: 27889629
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis and Biological Evaluation of a Structurally Simplified Syringolin A Analogues.
Chiba T; Kitahata S; Matsuda A; Ichikawa S
Chem Pharm Bull (Tokyo); 2016; 64(7):811-6. PubMed ID: 27373636
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
[TBL] [Abstract][Full Text] [Related]
15. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives.
Liu Y; Qian K; Wang CY; Chen CH; Yang X; Lee KH
Bioorg Med Chem Lett; 2012 Dec; 22(24):7530-3. PubMed ID: 23122524
[TBL] [Abstract][Full Text] [Related]
17. Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
Zhuang R; Gao L; Lv X; Xi J; Sheng L; Zhao Y; He R; Hu X; Shao Y; Pan X; Liu S; Huang W; Zhou Y; Li J; Zhang J
Eur J Med Chem; 2017 Jan; 126():1056-1070. PubMed ID: 28027531
[TBL] [Abstract][Full Text] [Related]
18. Noncovalent inhibitors of human 20S and 26S proteasome based on trypsin inhibitor SFTI-1.
Dębowski D; Cichorek M; Lubos M; Wójcik S; Łęgowska A; Rolka K
Biopolymers; 2016 Sep; 106(5):685-96. PubMed ID: 27258473
[TBL] [Abstract][Full Text] [Related]
19. Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition.
Clerc J; Groll M; Illich DJ; Bachmann AS; Huber R; Schellenberg B; Dudler R; Kaiser M
Proc Natl Acad Sci U S A; 2009 Apr; 106(16):6507-12. PubMed ID: 19359491
[TBL] [Abstract][Full Text] [Related]
20. Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors.
Huber EM; de Bruin G; Heinemeyer W; Paniagua Soriano G; Overkleeft HS; Groll M
J Am Chem Soc; 2015 Jun; 137(24):7835-42. PubMed ID: 26020686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
